Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Myeloproliferative neoplasm
ADR ID BADD_A06821
ADR Hierarchy
01      Blood and lymphatic system disorders
01.13      Haematopoietic neoplasms (excl leukaemias and lymphomas)
01.13.03      Myeloproliferative disorders (excl leukaemias)
01.13.03.006      Myeloproliferative neoplasm
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.21      Haematopoietic neoplasms (excl leukaemias and lymphomas)
16.21.03      Myeloproliferative disorders (excl leukaemias)
16.21.03.006      Myeloproliferative neoplasm
Description Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. [MeSH]
MedDRA Code 10077465
MeSH ID D009196
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Disorder myeloproliferative | Myeloproliferative disorder | Myeloproliferative disorder NOS | Myeloproliferative neoplasm | Myeloproliferative Disorders | Disorder, Myeloproliferative | Disorders, Myeloproliferative | Myeloproliferative Disorder
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00066Alendronic acid0.000053%
BADD_D00194Azacitidine0.000139%
BADD_D00318Busulfan0.000139%
BADD_D00511Clozapine0.002193%
BADD_D00549Cyclophosphamide--
BADD_D01110Hydroxyurea0.000208%
BADD_D01136Imatinib0.000347%
BADD_D01253Lenalidomide0.000453%
BADD_D01322Losartan0.000013%
BADD_D01336Macitentan0.000151%
BADD_D01952Ritonavir--
BADD_D01978Ruxolitinib0.000139%
BADD_D02031Sitaxentan--
BADD_D02331Valsartan0.000060%
BADD_D02365Vismodegib0.000139%
The 1th Page    1    Total 1 Pages